Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1557-1562

  Philippart, Patrick ^a   Harper, Luke ^a   Chaboteaux, Carole ^b   Decaestecker, Christine ^b   Bronckart, Yves ^b   Gordover, Laurence ^c   Lesueur Ginot, Laurence ^d   Malonne, Hughes ^b   Lavergne, Olivier ^d   Bigg, Dennis C H ^d   Mendes Da Costa, Pierre ^a   Kiss, Robert ^b  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

^d Institut Henri Beaufour   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BN 80245; CAMPTOTHECIN DERIVATIVE; DIFLOMOTECAN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR; IRINOTECAN; LACTONE DERIVATIVE; THYMIDINE; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTORADIOGRAPHY; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; TISSUE CULTURE;

ANTINEOPLASTIC AGENTS; BIOPSY; CAMPTOTHECIN; CELL DIVISION; COLON; COLONIC NEOPLASMS; CULTURE TECHNIQUES; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; THYMIDINE; TOPOTECAN; TRITIUM; TUMOR CELLS, CULTURED;

EID: 0034049602     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Cohen, A. M., Minsky, B. D., and Schilsky, R. L. Cancer of the colon. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 5, pp. 1144-1197. Philadelphia: Lippincott-Raven, 1997.
2. McCann, J. Colon cancer: new drug options improve on 5-FU. J. Natl. Cancer Inst., 90: 963-965, 1998.
3. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC), 246: 1046-1048, 1989.
4. Pommier, Y. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin. Oncol., 23: 3-10, 1996.
5. Pommier, Y., Pourquier, P., Fan, Y., and Strumberg, D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1400: 83-105, 1998.
6. Stewart, C. F., and Ratain, M. J. Topoisomerase interactive agents. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 5, pp. 452-467. Philadelphia: Lippincott-Raven, 1997.
7. Rowinsky, E. K., and Verweij, J. Review of phase I clinical studies with topotecan. Semin. Oncol., 24: S20-3-S20-10, 1997.
8. Cersosimo, R. J. Topotecan: a new topoisomerase I inhibiting antineoplastic agent. Ann. Pharmacother., 32: 1334-1343, 1998.
9. Rougier, P., and Bugat, R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin. Oncol., 23: 34-41, 1996.
10. Wiseman, L. R., and Markham, A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs, 52: 606-623, 1996.
11. Lavergne, O., Lesueur-Ginot, L., Rodas, F. P., and Bigg, D. C. H. BN80245: an E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorg. Med. Chem. Lett., 7: 2235-2238, 1997.
12. Lavergne, O., Lesueur-Ginot, L., Rodas, F. P., Kasprzyk, P. G., Pommier, J., Demarquay, D., Prevost, G., Ulibarri, G., Rolland, A., Schiano-Liberatore, A. M., Harnett, J., Pons, D., Camara, J., and Bigg, D. C. H. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J. Med. Chem., 41: 5410-5419, 1998.
13. Camby, I., Salmon, I., Danguy, A., Pasteels, J. L., Brotchi, J., Martinez, J., and Kiss, R. Influence of gastrin on human astrocytic tumor cell proliferation. J. Natl. Cancer Inst., 88: 594-600, 1996.
14. Janssen, T., Pétein, M., van Velthoven, R., De Decker, R., Assenmacher, C., Corbusier, A., Pasteels, J. L., Kiss, R., and Schulman, C. Coregulatory effects of epidermal growth factor, dihydrotestosterone and prolactin on benign human prostatic hyperplasia tissue culture proliferation. Prostate, 30: 47-52, 1997.
15. Bailly, C., Lansiaux, A., Dassonneville, L., Demarquay, D., Coulomb, H., Huchet, M., Lavergne, O., and Bigg, D. C. H. Homocamptothecin, an E-ring modified camptothecin analog, generates new topoisomerase I-mediated DNA breaks. Biochemistry, 38: 15556-15563, 1999.
16. Lesueur-Ginot, L., Demarquay, D., Kiss, R., Kasprzyk, P. G., Dassonneville, L., Bailly, C., Camara, J., Lavergne, O., and Bigg, D. C. H. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res., 59: 2939-2943, 1999.
17. Punt, C. J. A. New drugs in the treatment of colorectal carcinoma. Cancer (Phila.), 83: 679-689, 1998.
18. Vichi, P., and Tritton, T. R. Stimulation of growth in human and murine cells by Adriamycin. Cancer Res., 49: 2679-2682, 1989.